Nov 25, 2015
The much awaited consultation on a ‘new’ Cancer Drugs Fund (CDF) in England has finally emerged. Leela Barham reports.
Nov 20, 2015
There’s renewed optimism in the biomedical research community that years of effort finally may begin to pay off for developing cutting-edge gene and cellular treatments for debilitating and life-threatening conditions. Jill Wechsler reports.
Nov 18, 2015
The Senate hearing to weigh the appointment of Robert Califf to be the next commissioner of FDA was a fairly friendly event, with mostly softball questions about policies and programs. Jill Wechsler reports.
Nov 17, 2015
Large pharma companies have fallen “below legal and ethical standards” for making public information from the relevant clinical trials, according to a report from Bioethics International.
Nov 16, 2015
Pharmaceutical Executive
Building on our annual look at the industry's product pipeline, four key themes stand out that are driving the fast-changing environment for drug development, writes William Looney.
Nov 12, 2015
Pharmaceutical Executive
Rare disease supporters deliver inspiration and optimism—as well as promise of regulatory cooperation. Casey McDonald reports on this year's National Organization for Rare Disorders summit in Arlington, VA.
Nov 10, 2015
Ebola showed that when innovation is truly integrated, we can enter into unknown territories and bring new innovations with us, writes Neil Saward.
Nov 10, 2015
The new interim report on the UK's Accelerated Access Review, which aims to speed up access to innovation in the NHS, is lacking in detail, writes Leela Barham.
Nov 08, 2015
Some of the radical thinking on healthcare spending from a new EC specialist group offers robust food for thought, writes Reflector.
Nov 02, 2015
Public outrage over more high-priced drugs is undermining support for provisions in the House-passed 21st Century Cures legislation that provide additional exclusivities for developing certain new therapies, writes Jill Wechsler.
lorem ipsum